RACURA ONCOLOGY ORDINARY (RAC) Short Interest
RACURA ONCOLOGY ORDINARY (ASX:RAC) had 0.01% of shares reported as short positions as of 26 June 2026, representing 10,237 shares. RACURA ONCOLOGY ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
RAC
Racura Oncology
Pharmaceuticals, Biotechnology & Life Sciences
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Pharmaceuticals
Biotechnology
Oncology
Clinical Trials
Shorted
short percentage0.01%
reported shorts10.2K
shares on issue196.069M